Exchange: NASDAQ·Updated 04:48 PM EDT
News
all
press releases
Pictet Asset Management Holding SA Trims Stake in Amicus Therapeutics, Inc. $FOLD
Pictet Asset Management Holding SA lessened its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 70.6% during the fourth quarter, according to the company in its most...
MarketBeat
More News
Universal Beteiligungs und Servicegesellschaft mbH Decreases Holdings in Amicus Therapeutics, Inc. $FOLD
Universal Beteiligungs und Servicegesellschaft mbH cut its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 28.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 231,337 shares of the bi...
MarketBeat
Best Biotech Stocks To Add to Your Watchlist - April 28th
Danaher, Medpace, Vertex Pharmaceuticals, Oruka Therapeutics, Amicus Therapeutics, argenex, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...
MarketBeat
CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)
Key PointsIncreased Amicus Therapeutics stake by 1,476,861 shares; estimated trade size $21.17 million (based on average price from January to March 2026...
Nasdaq News: Markets
Amicus Therapeutics (NASDAQ:FOLD) Sets New 12-Month High - Time to Buy?
Amicus Therapeutics (NASDAQ:FOLD) Sets New 1-Year High - Should You Buy...
MarketBeat
Massachusetts Financial Services Co. MA Has $1.79 Million Position in Amicus Therapeutics, Inc. $FOLD
Massachusetts Financial Services Co. MA reduced its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 96.6% during the 4th quarter, according to the company in its most recent...
MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Share Price Crosses Above 200 Day Moving Average - Here's What Happened
Amicus Therapeutics (NASDAQ:FOLD) Shares Pass Above 200 Day Moving Average - What's Next...
MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Hold" by Brokerages
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have received an average recommendation of "Hold" from the thirteen analysts that are currently covering the stock, MarketBeat...
MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Hits New 1-Year High - Time to Buy?
Amicus Therapeutics (NASDAQ:FOLD) Hits New 1-Year High - Still a Buy...
MarketBeat
Capricorn Fund Managers Ltd Invests $3 Million in Amicus Therapeutics, Inc. $FOLD
Capricorn Fund Managers Ltd bought a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the...
MarketBeat
<
1
2
>

Advertisement|Remove ads.